Mesoblast Limited
(ASX:MSB) has announced a net loss attributable to shareholders of US$9.8 million for the first quarter of 2017.
The human stem-cell research company’s revenue fell to US$901,000 compared to around $4.14 million in revenue, for the prior corresponding period.
Mesoblast also reported a loss before income tax of about US$12.88 million.
It comes as R&D costs increased by US$7.4million compared to the prior corresponding period. Ongoing manufacturing and management expenses also contributed to the result.
Shares in Mesoblast Limited last traded 6.11% lower to $2.16.
